Artículo

Uncommon presentation of atypical hemolytic uremic syndrome: A Case Report

Martin, Sandra M. ; Balestracci, Alejandro ; Puyol, Iris ; Toledo, Ismael ; Cao, Gabriel Fernando Icon; Arizeta, Gema

Otros responsables

Fecha

09/2021

Editorial

Wolters Kluwer Medknow Publications

Revista

Indian Journal of Nephrology

Título del libro

Nombre del evento

Fecha del evento

Institución organizadora

ISSN

0971-4065

eISSN

ISBN

Idioma

Inglés

Tipo del evento

Clasificación temática

Resumen

Atypical hemolytic uremic syndrome (aHUS) is an ultra‑rare disease characterized by microangiopathic hemolytic anemia, thrombocytopenia and renal damage. Its presentation as nephrotic syndrome (NS) during first year of life is uncommon; we describe a child with clinical and laboratory findings of NS whose renal biopsy revealed thrombotic microangiopathy (TMA). A previously healthy 4‑month‑oldmale was admitted with severe dehydration, diarrhea and anuria. Laboratory results showed electrolyte disturbances, increased serum creatinine, anemia without schistocytes, thrombocytosis, normal lactic dehydrogenase (LDH) levels, hypoalbuminemia hypercholesterolemia and decreased C3 levels.After rehydration hematuria and massive proteinuria were also documented and an initial diagnosisof NS of the first year was established. Studies seeking for infectious agents were negative. Duringhospitalization he continued to be oligo-anuric needing dialysis and a renal biopsy was performed,which showed TMA findings. We here considered the diagnosis of aHUS and started plasmainfusions as a bridge until starting eculizumab. After two infusions urine output improved leading todiscontinuation dialysis. The diagnoses of STEC infection and thrombocytopenic thrombotic purpura were ruled out. Factor B, H, I and properdin levels were normal. Antibodies against CFH negative were negative. Screening for genes causative of aHUS detected a heterozygous variant in CFHR3 of uncertain significance. On day 20, treatment was switched to eculizumab, which induced a progressive remission of the NS. This case outlines the need for a heightened diagnosis suspicion of this already rare disease since early initiation of eculizumab therapy improves its prognosis.

Aprobación

Revisión

Complementado por

Referenciado por

Licencia Creative Commons

Excepto donde se indique lo contrario, la licencia de este ítem se describe como by-nc-sa